Can a new drug reduce bloodletting for polycythemia vera?

NCT ID NCT06290765

Terminated Disease control Sponsor: PharmaEssentia Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial investigates whether ropeginterferon alfa-2b can help people with polycythemia vera, a condition where the body makes too many red blood cells. The study will compare the drug to standard care, which includes phlebotomy (removing blood) and aspirin. About 70 adults with polycythemia vera who need frequent phlebotomies will participate. The goal is to see if the drug can keep blood cell levels under control and reduce the need for phlebotomy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ropeginterferon alfa-2b (P1101), given as a subcutaneous injection every two weeks
What this could lead to: If successful, this could offer a more effective treatment option for polycythemia vera, helping patients maintain healthy blood cell levels with fewer phlebotomies.
What could go wrong: This is a phase 4 trial with a relatively small number of participants (about 70), and results may not apply to all patients. The drug may cause side effects, and its benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASM POLYCYTHEMIA VERA

More trials for these conditions

Other studies related to the condition(s) this trial covers.